---
title: "Jazz and AbCellera sign deal for T-cell engagers in solid tumours"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290184636.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-06-18T09:33:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290184636.md)
  - [en](https://longbridge.com/en/news/290184636.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290184636.md)
generator: "portal-rs"
---

# Jazz and AbCellera sign deal for T-cell engagers in solid tumours

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)
- [ABCL.US](https://longbridge.com/en/quote/ABCL.US.md)

## Related News & Research

- [Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera](https://longbridge.com/en/news/297431759.md)
- [Jazz Pharma director Bruce C. Cozadd disposes of USD 1.79 million in ordinary shares](https://longbridge.com/en/news/297830909.md)
- [Jazz reports Phase III trial interim results for Ziihera combination](https://longbridge.com/en/news/298029886.md)
- [Jazz says FDA approves Ziihera combos for first-line HER2+ advanced gastroesophageal cancer](https://longbridge.com/en/news/297497068.md)
- [Jazz Pharma EVP Global Head of R&D and CMO Robert Iannone disposes of shares worth $19.23 million](https://longbridge.com/en/news/297568088.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**